Active	Status	Sponsor type	Region	Phase	Filter
8 Active 17 Inactive 25 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   - « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   Show only changed items Enrollment:

Advanced Filters

8 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Egrifta SV (tesamorelin acetate) / Theratechnologies, Massachusetts General Hospital
NCT03226821: Body Composition and Adipose Tissue in HIV	Completed	4	5	US	Tesamorelin, Egrifta	Columbia University, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	HIV Lipodystrophy Syndrome, Growth Hormone Deficiency, Body Composition	04/25	04/25
2004-002125-42: EFFECT OF PROLONGED TREATMENT WITH TH9507 ON IGF-I LEVELS IN ADOLESCENTS WITH ISOLATED GH DEFICIENCY DUE TO HYPOTHALAMIC PATHOGENESIS	Ongoing	3	12	Europe	Powder and solvent for solution for injection	AZIENDA SANITARIA OSPEDALIERA \"S. GIOVANNI BATTISTA DI TORINO\"	EVALUATION OF GROWTH HORMONE RELEASE
NCT02572323: Phase II Trial of Tesamorelin for Cognition in Aging HIV-Infected Persons	Completed	2	73	US	Tesamorelin, Egrifta	University of California, San Diego, University of Southern California, PalmTree Clinical Research Inc., University of California, San Francisco	Mild Cognitive Impairment	10/23	10/23
NCT03375788: Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk	Active, not recruiting	2	76	US	Tesamorelin, Egrifta, TH9507, Growth Hormone Releasing Hormone Analog, Identical Placebo	Massachusetts General Hospital	Non-Alcoholic Fatty Liver Disease, Obesity, Obesity, Abdominal, Liver Fat, Fatty Liver	07/24	01/25
TRIUMPH, NCT06554717: Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV	Not yet recruiting	2	100	US	Tesamorelin, Egrifta, TH9507, growth hormone-releasing hormone analogue, Placebo, Exercise	Massachusetts General Hospital, University of Colorado, Denver	HIV-1-infection, Frailty, Impaired Physical Function, Abdominal Obesity, Aging	01/28	06/28
NCT03150511: Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury	Recruiting	2	36	US	Tesamorelin 2 Milligrams (MG), Egrifta	Johns Hopkins University, United States Department of Defense	Peripheral Nerve Injuries	12/25	12/25
CARv3-TEAM-E T cells / Massachusetts General Hospital
INCIPIENT, NCT05660369: CARv3-TEAM-E T Cells in Glioblastoma	Recruiting	1	21	US	CARv3-TEAM-E T cells, Autologous T lymphocyte	Marcela V. Maus, M.D.,Ph.D.	Glioblastoma, Malignant Glioma, Recurrent Glioblastoma, Recurrent Glioma	01/26	01/27
NCT05024175: Long-term Follow-up of Subjects Treated with CAR T Cells	Recruiting	N/A	45	US	Disease assessments, Tumor Biopsy, Blood test	Massachusetts General Hospital	Long Term Adverse Effects, CAR-T, Duty to Follow Up, Adult, Progression-Free Survival, Disease-Free Survival, Overall Survival	08/38	08/39

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Egrifta SV (tesamorelin acetate) / Theratechnologies, Massachusetts General Hospital
NCT03226821: Body Composition and Adipose Tissue in HIV	Completed	4	5	US	Tesamorelin, Egrifta	Columbia University, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	HIV Lipodystrophy Syndrome, Growth Hormone Deficiency, Body Composition	04/25	04/25
2004-002125-42: EFFECT OF PROLONGED TREATMENT WITH TH9507 ON IGF-I LEVELS IN ADOLESCENTS WITH ISOLATED GH DEFICIENCY DUE TO HYPOTHALAMIC PATHOGENESIS	Ongoing	3	12	Europe	Powder and solvent for solution for injection	AZIENDA SANITARIA OSPEDALIERA \"S. GIOVANNI BATTISTA DI TORINO\"	EVALUATION OF GROWTH HORMONE RELEASE
NCT02572323: Phase II Trial of Tesamorelin for Cognition in Aging HIV-Infected Persons	Completed	2	73	US	Tesamorelin, Egrifta	University of California, San Diego, University of Southern California, PalmTree Clinical Research Inc., University of California, San Francisco	Mild Cognitive Impairment	10/23	10/23
NCT03375788: Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk	Active, not recruiting	2	76	US	Tesamorelin, Egrifta, TH9507, Growth Hormone Releasing Hormone Analog, Identical Placebo	Massachusetts General Hospital	Non-Alcoholic Fatty Liver Disease, Obesity, Obesity, Abdominal, Liver Fat, Fatty Liver	07/24	01/25
TRIUMPH, NCT06554717: Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV	Not yet recruiting	2	100	US	Tesamorelin, Egrifta, TH9507, growth hormone-releasing hormone analogue, Placebo, Exercise	Massachusetts General Hospital, University of Colorado, Denver	HIV-1-infection, Frailty, Impaired Physical Function, Abdominal Obesity, Aging	01/28	06/28
NCT03150511: Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury	Recruiting	2	36	US	Tesamorelin 2 Milligrams (MG), Egrifta	Johns Hopkins University, United States Department of Defense	Peripheral Nerve Injuries	12/25	12/25
CARv3-TEAM-E T cells / Massachusetts General Hospital
INCIPIENT, NCT05660369: CARv3-TEAM-E T Cells in Glioblastoma	Recruiting	1	21	US	CARv3-TEAM-E T cells, Autologous T lymphocyte	Marcela V. Maus, M.D.,Ph.D.	Glioblastoma, Malignant Glioma, Recurrent Glioblastoma, Recurrent Glioma	01/26	01/27
NCT05024175: Long-term Follow-up of Subjects Treated with CAR T Cells	Recruiting	N/A	45	US	Disease assessments, Tumor Biopsy, Blood test	Massachusetts General Hospital	Long Term Adverse Effects, CAR-T, Duty to Follow Up, Adult, Progression-Free Survival, Disease-Free Survival, Overall Survival	08/38	08/39